Restoring the Brain’s Natural Rhythms

Now recruiting patients for T-WAVE: A Phase 2 clinical trial examining an investigational oral drug, CX-8998, in people 16-55 years old with generalized epileptic syndromes with absence seizures. Participating patients will be allowed to stay on their medication for epilepsy.  LEARN MORE >>

  • Innovation
  • Discovery
  • Passion

Cavion is a clinical-stage pharmaceutical company developing first-in-class therapies to restore the brain’s natural rhythms by modulating overactive T-type calcium channels for a range of neurological and rare genetic diseases.  Cavion’s mission is to combine our deep understanding of T-type calcium channel (Cav3) biology with superior chemistry and clinical research innovation and expertise to provide therapeutics that will improve people’s lives.

Learn More

Cavion’s pipeline is comprised of best-in-class Cav3 modulators obtained from both internal drug discovery and in-licensing efforts.

Learn More

Cavion is pioneering new treatments to significantly improve the lives of people with movement disorders and other neurological diseases. As we work to bring these therapies to market, Cavion will use innovation to improve all aspects of trial conduct and patient engagement. Our clinical trials will integrate unobtrusive biometric monitoring devices that deliver meaningful data while causing less inconvenience for participants.

Learn More

Latest News

More +

Contact Us


Charlottesville Office
600 East Water Street, Suite E
Charlottesville, VA 22902
(Please contact the Charlottesville Office for all accounting related communications)

Cambridge Office
1 Broadway, 14 FL
Cambridge, MA 02142